Nebivolol is an antihypertensive specific ²1-adrenergic block drug. It is commercialized as a racemic mixture, D(+)(-)-nebivolol e L(-)(-)-nebivolol. The both enantiomers have different pharmacological activities, which suggests a different pharmacokinetics as well. Nebivolol metabolism is complex and it is subjected to genetic polymorphism of CYP2D6, responsible enzime by nebivolol metabolism. The kinect of nebivolol is enantiosselective on pacients extensive metabolisers, but not on poor metabolisers. Despite of this information, a few is known about nebivolol enantiosselective binding to plasma proteins. It is known that nebivolol binding is around 98% though. A technique used to quantify drugs on the drug-protein binding is capillary electrophoresis (CE). This technique allows the analysis of many compounds and it has been used to chiral drugs analysis. Therefore, the aim of this work is to evaluate enantioselective binding of nebivolol to plasma proteins by CE. The lack of information about this subject, suggests that this is an unpublished work.
News published in Agência FAPESP Newsletter about the scholarship: